Clinical trial
Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
NCT07927647 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 1,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metabolic dysfunction-associated steatohepatitis (mash), metabolic dysfunction-associated steatotic liver disease (masld), type 1 diabetes mellitus (t1d), type 2 diabetes mellitus (t2d)
Arms
As registered; 2 arms.
-
Control arms
Control arms with data from patients living with type 2 diabetes (T2D) who were previously included in the AngioSafe T2D cohort.
-
Study arm
Study arm comprising all consecutive adult patients living with type 1 diabetes who attend the day hospital units of the diabetology departments at Lariboisière and Bichat Hospitals (Paris), during which they undergo liver assessment using FibroScan as part of routine clinical care.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Comparison of circulating immune-cell subset frequencies according to liver status in patients with type 1 diabetes
Frequencies of circulating immune-cell subsets, expressed as percentages of the relevant parent cell population, will be quantified by multiparameter flow cytometry. Measurements will be compared across three liver-status groups defined by FibroScan: no steatosis (CAP \< 250 dB/m and liver stiffness \< 8 kPa), MASLD without elevated liver stiffness (CAP ≥ 250 dB/m and liver stiffness \< 8 kPa), and MASLD with elevated liver stiffness (CAP ≥ 250 dB/m and liver stiffness ≥ 8 kPa).
-
Comparison of circulating immune-cell gene expression profiles according to liver status in patients with type 1 diabetes
Transcriptomic profiles of circulating immune cells will be assessed using gene expression analysis. Differential gene expression between liver-status groups will be evaluated using normalized gene expression measurements and statistical analyses, as specified in the study protocol.
Lead sponsor's other trials
Assistance Publique - Hôpitaux de Paris, most recent start first.
+3,590 more trials See the organization page
Similar trials
Same condition (Fatty Liver) and phase, most recent start first.
+182 more trials See the condition page